Parasite proteins prompt immune system to fight off ovarian tumours in mice

Google+ Pinterest LinkedIn Tumblr +

400px-Toxoplasmosis2Scientists identified the specific proteins secreted by the parasite Toxoplasma gondii that cause the immune system in mice to attack established ovarian tumours.

The study, led by David Bzik of the Geisel School of Medicine at Dartmouth in Hanover, New Hampshire, is published in PLOS Genetics.

One promising strategy in the fight against cancer is to use the body’s own immune system to remove tumour cells, but due to a phenomenon called immune tolerance, the immune system has a difficult time identifying which cells to attack.

In the new study, scientists built upon previous discoveries that a safe, non-reproducing vaccine strain of T. gondii could cure mice of several types of solid tumours, and identified which parasite proteins and which immunological pathways are required to break immune tolerance.

ovaries fallopian tubes cervix_female reproductive system_oncology news australiaThey systematically deleted genes for secreted effector proteins–molecules that the parasite injects into a host cell to modulate the immune system during infection–and injected the altered parasites into mice with aggressive ovarian cancer.

Their results demonstrate that specific rhoptry and dense granule effector proteins that T. gondii secretes before and after host cell invasion, respectively, control the development of an effective host anti tumour response, and increase the survival of mice with ovarian tumours.

Using infectious organisms to break tumour immune tolerance may be an excellent therapeutic option for treating cancer in the future.

Currently, the use of the bacterium Listeria monocytogenes to break the immune tolerance of pancreatic tumours is being explored in clinical trials and T. gondii may be similarly useful.

By tracking and understanding which host cell pathways are manipulated by these T. gondii proteins, scientists can identify potential new targets to develop more effective therapies against highly aggressive solid tumours.
[hr] SourcePLOS Genetics

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Comments are closed.